四项临床失败！另，诺和诺德将停售一款产品，还有潜在致癌

Vertex is discontinuing research on the small molecule called VX-864 because of “non-serious rash events in some patients,” according to a press release. About three years ago, Vertex abandoned another AATD program, called VX-814, that made it to Phase II after seeing signs of liver damage. Verte x’s stock price moved down about 2% to $379 after markets closed Monday.

另一个，TYK2

Ventyx Biosciences has axed the development of its experimental psoriasis drug after lackluster Phase II results, sending its stock plummeting about 73% to $3.75 in premarket trading on Tuesday.

Its oral tyrosine kinase 2 inhibitor, VTX958, hit the primary and secondary endpoints of the trial — but did not show enough efficacy to support development, Ventyx CEO Raju Mohan said in a Monday statement.

另一个，酒精性肝炎

Durect (NASDAQ: DRRX) announced that its Phase 2b study of larsucosterol in severe alcohol-associated hepatitis did not meet its primary endpoint of a statistically significant reduction in mortality or liver transplantation at 90 days. Shares closed down 80% at $0.51.

特发性 嗜睡症

Phase 3 trial did not meet its primary endpoint, noted November 7, 2023. Phase 3 trial initiated, noted April 27, 2022. Phase 3 trial enrollment completed May 25, 2023.

诺和诺德停售长效地特胰岛素

Insulin powerhouse Novo Nordisk will discontinue its long-acting insulin Levemir in the US next year amid anticipated supply disruptions, a 65% price cut and as the company faces price negotiations with CMS for its other insulins

FAK抑制剂（希望它是）增强免疫疗法，为口服前药和小分子偶联药物又增证据

Treatment with the oral innate immune activator BXCL701 combined with pembrolizumab demonstrated prolonged overall survival in patients with metastatic castration-resistant prostate cancer of adenocarcinoma phenotype.

​

近日，某研究室致癌事件持续发酵，这让做那些氟烷麻醉剂的情何以堪？

专利保护创新，但不能过度​

​